AIM ImmunoTech Inc. — Director's Dealing 2019

Mar 13, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2019-02-27

Reporting Person: RODINO III PETER W. (Dir Govt Relations/Sectry)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-02-27	Series B Convertible Preferred Stock	X	18	—	Acquired	18	Direct
2019-02-27	Warrants	X	90000	—	Acquired	90000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-02-27	Subr Rights(to buy)	$1000	X	18	Acquired	2019-03-05	Pref Stk/Warrants ()	Direct

Footnotes

F1: Each share has a stated value of $1,000 and is convertible into 5,000 shares of common stock and was issued as part of a subscription right issued in a rights offering.

F2: Each warrant is exercisable for one share of common stock at an exercise price of $0.20 per share and was issued as part of a subscription right issued in a rights offering.

F3: Represents $1,000 per unit purchased in the rights offering, each unit consisting of 1 shares of Series B Preferred Stock and 5,000 warrants.